Five-Year Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
2017/3 2018/3 2019/3 2020/3 2021/3 2022/3 (forecast)
Net sales 98,781 101,448 114,716 116,637 121,885 135,000
 Pharmaceuticals 85,315 87,416 100,223 101,643 106,478 119,300
 Functional food 13,466 14,031 14,492 14,994 15,406 15,700
Operating income 15,280 17,079 20,644 21,668 26,134 28,000
Ordinary income 16,244 17,451 21,540 22,442 26,760 28,500
Net income attributable to owners of the parent 11,749 12,953 16,302 16,866 20,702 21,000
Depreciation and amortization 2,648 2,773 3,418 3,468 3,550 3,800
Capital investment 3,949 2,811 1,242 2,500 2,583 4,800
R&D expenses 14,903 13,221 16,701 13,994 16,104 26,500
Total assets 150,905 155,887 168,763 175,017 197,028
Net assets 114,316 125,689 135,190 145,760 162,543

Net Sales

In FY 2020, Nippon Shinyaku’s business performance continued to be affected by the COVID-19 pandemic in its domestic Pharmaceuticals and Functional Food segments. Nevertheless, net sales increased mainly thanks to the royalties from the overseas sales of Uptravi, Nippon Shinyaku’s originally developed treatment drug for pulmonary arterial hypertension, the growth of a range of new pharmaceuticals launched in Japan, and milestone income from Uptravi.

Operating income
 

Net income attributable to owners of the parent

The operating income was 26,134 million yen, 20.6% up from the previous term, and the net income attributable to owners of the parent 20,702 million yen, 22.7% up from the previous term, mainly due to increased sales and a lower cost to sales ratio resulting from the composition of sales items.

R&D expenses

Principal Financial Indicators

Fiscal year (yen) 2017/3 2018/3 2019/3 2020/3 2021/3
Earnings per share (EPS) 174.42 192.31 242.04 250.42 307.37
Dividend per share 48 52 70 86 99
Equity ratio 75.6 80.5 80.0 83.1 82.4
Return on equity (ROE) 10.8 10.8 12.5 12.0 13.5
Payout ratio 27.5 27 28.9 34.3 32.2

EPS / ROE

  • Earnings per share (EPS)
  • Return on equity (ROE)

Dividend per share / Payout ratio

  • Dividend per share
  • Payout ratio

Cash Flows

Fiscal year (millions of yen) 2017/3 2018/3 2019/3 2020/3 2021/3
Cash flow from operating activities 18,916 6,719 15,310 12,737 21,388
Cash flow from investing activities -5,750 -11,342 511 -2,339 -1,564
Cash flow from financing activities -2,193 -3,787 -3,708 -5,660 -6,199

Long-term Chronological Data

View long-term chronological data from here.